Skip Page Header

Home > Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16.

Pierce, John P and Benmarhnia, Tarik and Chen, Ruifeng and White, Martha and Abrams, David B and Ambrose, Bridget K and Blanco, Carlos and Borek, Nicolette and Choi, Kelvin and Coleman, Blair and Compton, Wilson M and Cummings, K Michael and Delnevo, Cristine D and Elton-Marshall, Tara and Goniewicz, Maciej L and Gravely, Shannon and Fong, Geoffrey T and Hatsukami, Dorothy and Henrie, James and Kasza, Karin A and Kealey, Sheila and Kimmel, Heather L and Limpert, Jean and Niaura, Raymond S and Ramôa, Carolina and Sharma, Eva and Silveira, Marushka L and Stanton, Cassandra A and Steinberg, Michael B and Taylor, Ethel and Bansal-Travers, Maansi and Trinidad, Dennis R and Gardner, Lisa D and Hyland, Andrew and Soneji, Samir and Messer, Karen (2020) Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. PLoS ONE , 15 , (9) , e0237938.

URL: https://journals.plos.org/plosone/article?id=10.13...

BACKGROUND: More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy.

OBJECTIVE: To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.
DESIGN: Cohort study of US sample, with annual follow-up.

PARTICIPANTS: US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443).
EXPOSURES: Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2.
ANALYSIS: Propensity score matching (PSM) of groups using different methods to quit.
OUTCOME MEASURES: 12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome.

RESULTS: Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products.

LIMITATIONS: The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA.

CONCLUSION: Among US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.


Item Type
Article
Publication Type
International, Open Access, Article
Drug Type
Tobacco / Nicotine
Intervention Type
Drug therapy, Treatment method
Source
Date
September 2020
Page Range
e0237938
Volume
15
Number
9
EndNote

Repository Staff Only: item control page